

CivaTech Oncology announces advances in prostate cancer treatment as patients return to normal urinary and sexual function quickly

RESEARCH TRIANGLE PARK, N.C. - A recent study has shown that CivaString®, the only polymer-based, implantable radiation device, produces significant improvements in patients treated for prostate cancer. In a study of 37 patients over two years, Drs. Brad Prestidge, Richard Stock, and Brian Moran report that patients more quickly return to normal urinary function and normal sexual activity following a CivaString® procedure. Also pain and swelling from treatment is reduced up to 40 percent compared to competitive metal brachytherapy seeds.

CivaString®, developed and manufactured by CivaTech Oncology, was designed to be implanted in as little as 15 minutes and requires fewer needles than other brachytherapy devices. Procedures generally take less than one hour, and patients return home the same day. No follow-up procedure is necessary to remove the devices. CivaString® is effective and convenient for patients who will quickly resume their daily routines. They report they are satisfied with the procedure and outcomes. “Your product really did the trick,” said one patient. “I’m 75 and back playing racquet ball.”

This advanced therapy option is covered by Medicare and private payers with its own unique code. Approximately 180,000 patients annually in the U.S. are diagnosed with prostate cancer and face the difficult decision of choosing the “right” therapy. About a third of those patients choose radiation therapy, because it is consistently effective with the least negative impact on quality of life. CivaTech Oncology focuses on designing improved radiation products to target cancer while maintaining the best quality of life possible for patients. Additionally, CivaString® has broad FDA clearance to treat many types of cancer. For more information, please visit www.civatechoncology.com

About CivaTech Oncology:

CivaTech Oncology’s products bring meaningful improvements to provide targeted radiation therapy.

Contacts:

CivaTech Oncology Inc.

Randy Harrison, 919-314-5515

National Sales Manager
rharrison@civatechoncology.com